Visterra develops innovative antibody-based therapies for difficult-to-treat diseases like kidney and immune-mediated disorders, using its proprietary technology platform to create precision candidates targeting key disease mechanisms. With a robust pipeline including clinical-stage assets and an approved therapy, sibeprenlimab, Visterra stands out as a nimble biotech firm backed by the stability of the Otsuka family of companies.
No jobs found. Subscribe below to get notified when we find something for you.
Searching